Health Care [ 8/12 ] | Biotechnology [ 36/76 ]
NASDAQ | Common Stock
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001.
Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 12, 24 | -1.25 Decreased by -3.02 K% | -2.38 Increased by +47.48% |
| Jul 27, 24 | -13.35 Decreased by -44.40 K% | -2.75 Decreased by -385.45% |
| Mar 25, 24 | -0.38 Decreased by -533.33% | -0.32 Decreased by -18.75% |
| Dec 15, 23 | -0.44 Decreased by -1.37 K% | -0.67 Increased by +34.33% |
| Sep 13, 23 | -0.04 Decreased by -33.33% | -0.04 |
| Jul 27, 23 | -0.03 Increased by +25.00% | -0.04 Increased by +25.00% |
| Mar 15, 23 | -0.06 Decreased by -100.00% | -0.04 Decreased by -50.00% |
| Dec 12, 22 | -0.03 Increased by +25.00% | -0.04 Increased by +25.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Apr 30, 24 | 76.11 K Increased by +N/A% | -851.53 K Increased by +74.24% | Decreased by -1.12 K% Decreased by N/A% |
| Jan 31, 24 | 0.00 Decreased by N/A% | -2.66 M Increased by +50.95% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 23 | 0.00 Decreased by N/A% | -2.91 M Increased by +6.67% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 23 | 0.00 Decreased by N/A% | -3.53 M Decreased by -16.10% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 23 | 0.00 Decreased by N/A% | -3.31 M Increased by +14.50% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 23 | 0.00 Decreased by N/A% | -5.43 M Decreased by -110.96% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 22 | 0.00 Decreased by N/A% | -3.11 M Increased by +13.51% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 22 | 0.00 Decreased by N/A% | -3.04 M Decreased by -30.98% | Decreased by N/A% Decreased by N/A% |